BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Biogen Inc.

225 Binney Street
Cambridge, MA 02142
United States
617-679-2000
http://www.biogen.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees7,300

Key Executives

NameTitlePayExercisedYear Born
Mr. Michel VounatsosCEO & Director2.65MN/A1962
Dr. Michael D. EhlersExec. VP and Head of R&D2.1MN/A1969
Mr. Jeffrey D. CapelloExec. VP of Fin. & CFON/AN/A1965
Mr. Gregory F. CovinoVP of Fin. & Chief Accounting OfficerN/AN/A1966
Mr. Mark J. HernonSr. VP & Chief Information OfficerN/AN/A1964
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. The company's Phase II clinical trial products comprise Opicinumab for MS; BAN2401 for Alzheimer's disease; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild AD. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Biogen Inc.’s ISS Governance QualityScore as of April 1, 2018 is 1. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 3; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.